Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference

Rigel (Nasdaq: RIGL) announced that Raul Rodriguez, president and CEO, will present a company overview at the 44th Annual J.P.

Rhea-AI Summary

Rigel (Nasdaq: RIGL) announced that Raul Rodriguez, president and CEO, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026 at 3:00 PM PT (6:00 PM ET).

The presentation will be available via live webcast and archived recording through Rigel's Investor Relations site at www.rigel.com; investors are advised to connect to the website before the start to allow any required software downloads.

Argus Jan 7 session

+8.66% close to close 1.4x rel. volume Open Argus

Details

News Market Reaction – RIGL

On Jan 7, the day this news came out, RIGL closed 8.66% above the previous close.

Data tracked by StockTitan Argus for the Jan 7 session.

Key Figures

Conference edition: 44th annual Presentation date: January 14, 2026 Presentation time PT: 3:00 p.m. PT +5 more

Conference edition

44th annual

J.P. Morgan Healthcare Conference

Presentation date

January 14, 2026

J.P. Morgan Healthcare Conference slot

Presentation time PT

3:00 p.m. PT

Conference presentation start time

Presentation time ET

6:00 p.m. ET

Conference presentation start time

Company founding year

1996

Rigel founding date

Current price

$43.28

Pre‑news close

1-day change

5.07%

Price change over prior 24h pre‑news

52-week range

$15.50 – $52.24

Trailing 52-week low and high

Historical Context

5 past events · Latest: Nov 26

5 events

1. Nov 26

   Conference appearance

   24h Move

   +2.8%

   Piper Sandler healthcare conference presentation with webcast access details.

2. Nov 17

   Clinical data update

   24h Move

   +1.4%

   Publication of final 5-year REZLIDHIA Phase 2 data in R/R mIDH1 AML.

3. Nov 12

   Conference appearance

   24h Move

   +5.2%

   Jefferies Global Healthcare Conference presentation and webcast details.

4. Nov 04

   Earnings update

   24h Move

   -7.4%

   Strong Q3 2025 revenues, net income, and raised full‑year guidance.

5. Nov 03

   Scientific meeting data

   24h Move

   -2.9%

   Multiple ASH presentations with updated R289 and REZLIDHIA clinical data.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

hematologic disorders

1 terms

hematologic disorders medical

"novel therapies that significantly improve the lives of patients with hematologic disorders and cancer."

Hematologic disorders are diseases that affect the blood and the organs that make blood, such as conditions causing low blood counts, abnormal clotting, or cancers of blood-forming cells. For investors, these disorders matter because they define markets for diagnostics, treatments and long-term care—think of them as problems in a city’s delivery and maintenance system: fixing them can create commercial opportunities, while persistent unmet needs can drive regulatory attention and spending.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Jan. 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 14, 2026 at 3:00 p.m. PT (6:00 p.m. ET).

To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads.

About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com.

Contact for Investors & Media:
Investors: 
Rigel Pharmaceuticals, Inc. 
650.624.1232 
ir@rigel.com

Media:
David Rosen 
Argot Partners 
646.461.6387
david.rosen@argotpartners.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-302654554.html

SOURCE Rigel Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Rigel (RIGL) present at the J.P. Morgan Healthcare Conference in 2026?

Rigel will present on January 14, 2026 at 3:00 PM PT (6:00 PM ET).

Who from Rigel (RIGL) will speak at the January 14, 2026 presentation?

Raul Rodriguez, Rigel's president and CEO, will deliver the company overview.

How can investors watch Rigel's (RIGL) live webcast for the J.P. Morgan presentation?

Access the live webcast and archived recording via Rigel's Investor Relations site at www.rigel.com.

Will Rigel (RIGL) provide a recording of the January 14, 2026 J.P. Morgan presentation?

Yes, an archived recording will be available on the company's Investor Relations website after the live webcast.

What should viewers do before joining Rigel's (RIGL) live webcast on January 14, 2026?

Connect to Rigel's website prior to the start time to allow any required software downloads.

Is Rigel's (RIGL) J.P. Morgan presentation focused on products or company strategy?

The company listed it as a company overview, covering recent developments and corporate outlook.